A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-503114-23-00

Acronym

STML-ELA-0222

Enrollment

320

Registered

2023-10-20

Start date

2023-12-19

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026